N-methyl-2,6-bis(trifluoromethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-2,6-bis(trifluoromethyl)benzamide
• 化学式: C₁₀H₇F₆NO
• 分子量: 271.16
• InChiKey: AHSGBJURNKOOOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] ADOPTIVE CELLULAR THERAPY USING AN AGONIST OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA & RELATED THERAPEUTIC METHODS<br/>[FR] THÉRAPIE CELLULAIRE ADOPTIVE UTILISANT UN AGONISTE DU RÉCEPTEUR GAMMA ORPHELIN ASSOCIÉ AU RÉCEPTEUR DE L'ACIDE RÉTINOÏQUE ET MÉTHODES THÉRAPEUTIQUES ASSOCIÉES
  申请人：LYCERA CORP

  公开号：WO2015131035A1

  公开（公告）日：2015-09-03

  The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.

  该发明涉及使用视黄酸受体相关孤儿受体γ（RORγ）激动剂进行医学疗法，并提供使用RORγ激动剂的免疫细胞疗法，包括暴露于RORγ激动剂的淋巴细胞群、暴露于RORγ激动剂的树突细胞群、制药组合物以及通过向患者施用RORγ激动剂来增强患者体内淋巴细胞和/或树突细胞的治疗效果的方法。
• N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：Glick Gary D.

  公开号：US20140088094A1

  公开（公告）日：2014-03-27

  The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

  本发明提供四氢喹啉及相关化合物、制药组合物、抑制RORγ活性的方法、减少受试者体内IL-17的数量以及使用该四氢喹啉及相关化合物治疗免疫性疾病和炎症性疾病的方法。
• BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150126493A1

  公开（公告）日：2015-05-07

  The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.

  本发明提供了双环磺酮化合物、制药组合物、抑制RORy活性、减少受试者中IL-17含量以及使用这些双环磺酮化合物治疗免疫障碍和炎症性疾病的方法。本发明的另一方面提供了治疗医学疾病的方法。该方法包括向受试者施用所述的一种或多种双环磺酮化合物的治疗有效量。在某些其他实施例中，该疾病是类风湿性关节炎。
• Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease
  申请人：Lycera Corporation

  公开号：US20150133437A1

  公开（公告）日：2015-05-14

  The invention provides tetrahydro[1,8]naphthyridine and related compounds, methods of promoting RORy activity and/or increasing the amount of iL-17 in a subject, and therapeutic uses of the tetrahydro[1,8]naphthyridine and related compounds. In particular, the invention provides sulfonamide-tetrahydro[1,8]naphthyridine and related compounds, methods of using such compounds to promote RORy activity and/or increase the amount of iL-17 in a subject, and treat medical conditions in which activation of immune response would be beneficial such as in cancer and infections.

  该发明提供了四氢[1,8]萘啶及其相关化合物，促进RORy活性和/或增加主体中iL-17数量的方法，并且提供了四氢[1,8]萘啶及其相关化合物的治疗用途。特别地，该发明提供了磺酰胺-四氢[1,8]萘啶及其相关化合物，使用这些化合物促进RORy活性和/或增加主体中iL-17数量的方法，并治疗激活免疫反应有益的医疗状况，如癌症和感染。
• Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
  申请人：Lycera Corporation

  公开号：US10208061B2

  公开（公告）日：2019-02-19

  The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

  本发明提供了四氢[1,8]萘啶及相关化合物、药物组合物、促进 ROR 活性的方法、增加受试者体内 IL-17 含量的方法以及使用此类四氢[1,8]萘啶及相关化合物治疗癌症的方法。